Healthcare · NSE: SUNPHARMA · BSE: 524715
Sun Pharma: how the business works
Sun Pharma makes medicines sold in more than 100 countries, including India and the US, earning ₹58,462 crore of revenue in FY26.
Follow Sun Pharma
Email me when Sun Pharma's page is updated after results.
We store your email address with Kit, our email provider, which also records when you sign up and whether you open or click our emails. We send a confirmation email first. See our privacy policy.
Sun Pharmaceutical Industries Limited · Mumbai, Maharashtra · Founded 1983
Updated for Q2 FY27 · checked
- Revenue, FY26
- ₹58,462 cr
- Profit to shareholders, FY26
- ₹11,479 cr
- Manufacturing plants (group)
- 40
- Employees (group)
- 47,000+
- Promoter holding, 30 Sep 2026
- 52.68%
The short version
Sun Pharma in 5 points
1 · What it sells
Sun Pharma makes branded medicines for India, generic medicines for the US and other countries, and patented drugs such as Ilumya, and its FY26 revenue from operations was ₹58,462 crore.
2 · Who pays it
In FY26, buyers in India paid 33.8% of Sun Pharma's sales, buyers in the US 30.3%, emerging markets 20.1% and the rest of the world 15.8%.
3 · What it keeps from ₹100
Of every ₹100 that came in during FY26, Sun Pharma kept ₹19.0 as profit after ₹2.2 of one-off charges, and in Q2 FY27 a ₹1,269 crore one-off charge cut profit to ₹1,989 crore while profit before one-off items and tax rose 6.3% to ₹4,428 crore.
4 · Where the operating profit comes from
Sun Pharma does not report profit by region or product, so the source of its FY26 EBITDA of ₹16,424 crore is not disclosed; patented innovative medicines were 20.7% of its sales, excluding a milestone payment.
5 · The one thing to watch
Sun Pharma agreed on 27 Apr 2026 to buy Organon, a company with US$6.2 billion of 2025 revenue, for an enterprise value of US$11.75 billion, and management said on 30 Oct 2026 it expects completion in Q4 FY27.
Sources: From Sun Pharma's FY26 annual report, its Q2 FY27 results, release and earnings call, and its 27 Apr 2026 Organon announcement · checked
Sources (6)
- Annual Report FY26: Consolidated Financial Statements section
- Annual Report FY26: Chairman/MD message and Management Discussion & Analysis section
- Unaudited consolidated financial results Q2 FY27 (quarter and half year ended 30 Sep 2026)
- Press release: Sun Pharma reports Q4FY26 and FY26 results
- Intimation and press release: definitive agreement to acquire Organon & Co.
- Q2 FY27 earnings call transcript (call 30 Oct 2026)
01Where the money goes · FY26
Where does ₹100 of Sun Pharma's money go?
Sun Pharma · FY26
Receipt for every ₹100
| Materials and goods bought | ₹19.1 |
|---|---|
| Employee costs | ₹18.9 |
| Other running costs (research, marketing, freight) | ₹29.4 |
| Depreciation, interest and small items | ₹5.5 |
| One-off charges | ₹2.2 |
| Income tax | ₹5.9 |
| Kept as profit for shareholders | ₹19.0 |
| Total | ₹100 |
Each line = amount ÷ total money in × 100. Lines may not add to exactly ₹100 because of rounding.
How this is worked out
Of every ₹100 that came in during FY26 (revenue of ₹58,462 crore plus ₹1,972 crore of other income), Sun Pharma kept ₹19.0 as profit for shareholders, after ₹2.2 of one-off charges.
Save this receipt as an image
Embed this receipt or the key numbers
Paste this code into a blog or website to show the card you choose, with a link back to this page.
Each week: the next company due to report results, explained in 5 points.
We'll email you once a week with what changed on Cityfort. Facts only, no tips. Unsubscribe any time.
We store your email address with Kit, our email provider, which also records when you sign up and whether you open or click our emails. We send a confirmation email first. See our privacy policy.
02The business in one line
What does Sun Pharma do?
Buyers in more than 100 countries, including India and the US, pay Sun Pharma for its medicines; most of the money goes on research, marketing, staff and materials, and ₹19 of every ₹100 was left as profit in FY26.
- In FY26 India gave 33.8% of Sun Pharma's sales, the US 30.3%, emerging markets 20.1% and the rest of the world 15.8%.
- Of every ₹100 that came in during FY26, ₹29.4 went on running costs such as research and marketing, ₹19.1 on materials and ₹18.9 on staff.
03Who pays it
Who pays Sun Pharma?
Buyers in India
33.8%
of revenue
Medicines sold in India, mostly under Sun Pharma's brands. Its sales team of over 16,000 people visits doctors. Share is of FY26 sales; drug-ingredient sales are counted in the region where they were sold.
Buyers in the US
30.3%
of revenue
Generic and innovative medicines sold in the US. US formulation sales were US$1,904 million in FY26.
Buyers in emerging markets
20.1%
of revenue
Medicines sold in emerging markets. Formulation sales there were US$1,265 million in FY26, up 13%.
Buyers in the rest of the world
15.8%
of revenue
Medicines sold in other countries. Formulation sales there were US$969 million in FY26, up 14%.
- Buyers in India33.8%
- Buyers in the US30.3%
- Buyers in emerging markets20.1%
- Buyers in the rest of the world15.8%
How spread out the customers are
No single customer gave Sun Pharma 10% or more of revenue in any year from FY22 to FY26, according to its segment note. The documents collected do not say how much its largest US buyers take.
04How it makes money
How does Sun Pharma make money?
Medicines cost little to make; the money goes on research, marketing and staff, and new products decide growth.
Materials took ₹19.1 of every ₹100 that came in during FY26. The bigger costs are research, marketing and a sales team that visits doctors. Sales of Sun Pharma's patented innovative medicines rose from US$871 million in FY23 to US$1,420 million in FY26.
Innovative medicines sales (US$ million)
8711,420
FY23 to FY26
- Over 16,000 field staff explain Sun Pharma's brands to doctors in India.
- Doctors prescribe them: Sun Pharma had 30 of India's top 300 brands (AIOCD, Jun 2026).
- In the US it sells generics of off-patent drugs and its own patented medicines.
- Materials cost ₹19.1 of every ₹100 that came in during FY26.
- It spent ₹3,554 crore, 6.1% of sales, on research in FY26.
- Research brings new products, such as Ilumya for psoriatic arthritis in the US.
↺ Step 6 feeds back into step 1.
05Business segments · FY26
Which businesses make up Sun Pharma?
India
33.8%Sales in India, mostly branded medicines, plus drug ingredients sold there.
Revenue ₹19,694 cr
United States
30.3%Generic and patented medicines sold in the US.
Revenue ₹17,620 cr
Emerging markets
20.1%Sales in emerging markets outside India.
Revenue ₹11,684 cr
Rest of the world
15.8%Sales in all other countries.
Revenue ₹9,222 cr
How the mix changed
- India
- United States
- Emerging markets
- Rest of the world
Revenue by segment, FY22 to FY26.
₹ crore
See the numbers
06The numbers · Consolidated · ₹ crore
How has Sun Pharma done?
Revenue
₹58,462 crFY26
Revenue rose every year, from ₹38,655 crore in FY22 to ₹58,462 crore in FY26, and reached ₹16,199 crore in Q2 FY27.
₹ crore
See the numbers
Net profit
₹11,479 crFY26
FY22 profit of ₹3,273 crore came after a ₹4,567 crore one-off charge, mainly a US antitrust settlement, so FY23's 158.9% rise is mostly a base effect; Q2 FY27 profit fell 36.2% to ₹1,989 crore after a ₹1,269 crore one-off charge, while profit before one-off items and tax rose 6.3% to ₹4,428 crore.
₹ crore
See the numbers
Net profit for every ₹100 of revenue
₹19.6FY26
Net profit per ₹100 of revenue was between ₹19.3 and ₹20.8 from FY23 to FY26, against ₹8.5 in FY22, the year of the large settlement charge.
Net margin: ₹ of net profit per ₹100 of revenue
See the numbers
Free cash flow
₹8,810 crFY26
Free cash flow fell from ₹11,944 crore in FY25 to ₹8,810 crore in FY26, as capital spending rose to ₹3,609 crore and income tax paid rose to ₹2,314 crore.
₹ crore · cash from operations minus spending on plants and equipment
See the numbers
See all yearly numbers
EBITDA = profit before interest, tax and wear-and-tear of assets. Financial year runs April to March (March year end). Net profit is the share belonging to the company's owners.
Sources (8)
- Annual Report FY23: Consolidated Financial Statements section
- Annual Report FY24: Consolidated Financial Statements section
- Annual Report FY25: Consolidated Financial Statements section
- Annual Report FY26: Consolidated Financial Statements section
- Unaudited consolidated financial results Q3 FY26 (quarter ended 31 Dec 2025)
- Audited consolidated financial results Q4 FY26 and FY26
- Unaudited consolidated financial results Q1 FY27 (quarter ended 30 Jun 2026)
- Unaudited consolidated financial results Q2 FY27 (quarter and half year ended 30 Sep 2026)
07Who runs it
Who runs Sun Pharma, and did they deliver?
Dilip S. Shanghvi
Executive Chairman · since 2025
Managing Director until 31 Aug 2025; Executive Chairman from 1 Sep 2025 to 31 Aug 2030. Held 9.60% of the shares directly on 30 Sep 2026.
Kirti Ganorkar
Managing Director · since 2025
Managing Director from 1 Sep 2025 to 31 Aug 2030.
Jayashree Satagopan
Chief Financial Officer · since 2025
CFO from 1 Jul 2025, after C.S. Muralidharan retired.
Aalok Shanghvi
Whole-time Director and Chief Operating Officer
Vidhi Shanghvi
Whole-time Director · since 2025
Whole-time Director from 22 May 2025.
What they said, and what happened
1 delivered · 4 too early to tell
Said on 22 May 2025
Management expected "mid to high single digit" consolidated revenue growth in FY26, with research at 6–8% of sales.
DeliveredWhat happened
FY26 revenue rose 11.2% (sales 11.9%), and research was 6.1% of sales.
Said on 22 May 2026
Management expected "high single-digit" consolidated revenue growth in FY27, with research at 6–7% of sales.
Too early to tellWhat happened
In H1 FY27 sales rose 11.0% and research was 5.1% of sales. On 30 Oct 2026 management said research spending would rise significantly in later quarters.
Said on 27 Apr 2026
Sun Pharma expected to complete the purchase of Organon & Co. in early 2027.
Too early to tellWhat happened
Not closed as of the 30 Oct 2026 earnings call, where management said approvals were secured in most regions and gave Q4 FY27 as the expected timing.
Said on 2 Dec 2025
Build a ₹3,000 crore formulations plant in Madhya Pradesh, through subsidiary Sun Pharma Laboratories.
Too early to tellWhat happened
No completion date has been filed.
Said on 30 Oct 2026
Start a soft US launch of Ilumya for psoriatic arthritis in November 2026, with a full launch in the following months.
Too early to tellWhat happened
Not yet reported.
Sources (11)
- Annual Report FY26: Board's Report and Corporate Governance section
- Shareholding pattern as of 30 Sep 2026 (NSE XBRL)
- Q4 FY25 earnings call transcript (call 22 May 2025)
- Annual Report FY26: Consolidated Financial Statements section
- Press release: Sun Pharma reports Q4FY26 and FY26 results
- Q4 FY26 earnings call transcript (call 22 May 2026)
- Press release: Sun Pharma reports Q2FY27 results
- Q2 FY27 earnings presentation
- Q2 FY27 earnings call transcript (call 30 Oct 2026)
- Intimation and press release: definitive agreement to acquire Organon & Co.
- Intimation: approval of ₹3,000 crore greenfield formulations facility in Madhya Pradesh
08What could go wrong
What could go wrong for Sun Pharma?
- Regulation
US FDA and quality checks at plants
Four Indian plants carry US FDA findings, and Halol has been on an import alert since Dec 2022. In Aug 2026 Sun Pharma recalled 11 eye-care products from its Assam plant and paused production there.
Watch New FDA inspection results for Halol, Mohali, Dadra and Baska, and the restart of the Assam plant.
- Debt
Organon purchase and new debt
The Organon purchase has not closed. CRISIL says it will be funded with US$2.0–2.5 billion of cash and US$9.5–10.0 billion of debt. Sun Pharma's borrowings were ₹2,694 crore on 30 Sep 2026. Organon deal costs were ₹513 crore in H1 FY27, and Sun Pharma expects more.
Watch Completion of the deal (management expects Q4 FY27) and borrowings in the first balance sheet after it.
- Competition
Falling US generic sales
US formulation sales fell 8.2% in US dollars in Q2 FY27, to US$455 million; management said this was largely due to lower lenalidomide sales. CRISIL notes price pressure in US generics from authorised generics, buyer consolidation and other Indian makers.
Watch US formulation sales in US dollars each quarter.
- Legal
US lawsuits and settlements
One-off charges for US legal settlements recur: ₹3,723 crore in FY22, US$200 million in FY26 and ₹923 crore in Q2 FY27, all settled without admitting wrongdoing. In Aug 2026 a US appeals court ruled for Sun Pharma in the Lipitor antitrust case.
Watch Further charges in the US generic-drug pricing antitrust case.
- Regulation
US drug pricing and tariffs
Management said on 30 Oct 2026 that it agreed with the US government to offer most-favoured-nation (MFN) prices to state Medicaid programmes, and that this delays Section 232 tariffs on its innovative products for over 2 years. CRISIL lists US tariffs and MFN pricing as risks.
Watch Changes to US drug-pricing and tariff rules, and US innovative-medicine sales.
- Governance
Small promoter pledge
On 30 Sep 2026, 85,000 promoter-group shares held by Kumud Shantilal Shanghvi were pledged, 0.01% of the promoter holding. Pledged shares are given as loan collateral; a lender can sell them if a loan is not repaid.
Watch Pledged share of the promoter holding in each quarterly shareholding filing.
Sources (11)
- Annual Report FY26: Consolidated Financial Statements section
- Intimation: US FDA classifies Baska facility inspection as OAI
- Q2 FY27 earnings call transcript (call 30 Oct 2026)
- Credit rating intimation with CRISIL rationale (13 Oct 2026, NCDs assigned AAA/Stable) and ICRA rationale
- Unaudited consolidated financial results Q2 FY27 (quarter and half year ended 30 Sep 2026)
- Press release: Sun Pharma reports Q2FY27 results
- Annual Report FY23: Consolidated Financial Statements section
- Intimation: settlement agreement with a plaintiff in the generic drug pricing antitrust litigation (US)
- Intimation: update on Lipitor antitrust litigation (US appeals court affirms judgment for the company)
- Shareholding pattern as of 30 Sep 2026 (NSE XBRL)
- Shareholding pattern as of 30 Jun 2026 (NSE XBRL)
09Supporters and critics
What do supporters and critics point to?
What supporters point to
- Revenue rose every year from FY22 to FY26, from ₹38,655 crore to ₹58,462 crore.
- India formulation sales rose 17.3% in Q2 FY27, to ₹5,552 crore; Sun Pharma had 8.5% of India's medicine market (AIOCD, 12 months to Jun 2026).
- Innovative medicine sales rose from US$871 million in FY23 to US$1,420 million in FY26.
- On 30 Sep 2026 cash and liquid investments exceeded borrowings by ₹30,877 crore. CRISIL rates it AAA/Stable; Moody's gave Baa1 and S&P BBB+ in Sep 2026.
- Sun Pharma says Organon would add US$6.2 billion of 2025 revenue and make it a top-3 company worldwide in women's health.
What critics point to
- Q2 FY27 profit fell 36.2% to ₹1,989 crore, after a ₹1,269 crore one-off charge.
- US formulation sales fell 8.2% in US dollars in Q2 FY27, to US$455 million.
- Four plants carry US FDA findings, and Halol has been on an import alert since Dec 2022.
- CRISIL says Organon funding includes US$9.5–10.0 billion of debt, against borrowings of ₹2,694 crore on 30 Sep 2026.
- One-off charges, mostly US legal settlements, impairments and restructuring, cut profit in every year from FY22 to FY26: ₹1,308 crore in FY26.
10What to watch next
What should you watch next at Sun Pharma?
Next event
Q3 FY27 results
Date not announced yet.
Organon deal completion
Management said on 30 Oct 2026 that it expects to complete the purchase in Q4 FY27 (Jan–Mar 2027). The first balance sheet after it will show the new debt.
US sales
US formulation sales fell 8.2% in US dollars in Q2 FY27, to US$455 million. Management said on 30 Oct 2026 that Ilumya for psoriatic arthritis would have a soft US launch in November, then a full launch in the following months.
Plant inspections
Any new US FDA result for Halol, Mohali, Dadra or Baska, and whether production restarts at the Assam eye-care plant.
11Key facts
Key facts about Sun Pharma
- What does Sun Pharma do?
- Sun Pharmaceutical Industries Ltd (Sun Pharma) makes and sells medicines in more than 100 countries, including India and the US. Sun Pharma's corporate office is in Mumbai and its registered office in Vadodara. Its FY26 revenue from operations was ₹58,462 crore.
- How does Sun Pharma make money?
- Sun Pharma sells branded medicines in India, generic (off-patent) medicines in the US and other countries, and patented innovative medicines such as Ilumya. In FY26 Sun Pharma's innovative medicines sold US$1,420 million, 20.7% of its sales excluding a milestone payment.
- Who are Sun Pharma's customers?
- In FY26 Sun Pharma's sales came 33.8% from India, 30.3% from the US, 20.1% from emerging markets and 15.8% from the rest of the world. No single customer gave Sun Pharma 10% or more of its FY26 revenue.
- How big is Sun Pharma?
- Sun Pharma's FY26 revenue was ₹58,462 crore and its profit for shareholders was ₹11,479 crore. Its FY26 EBITDA (profit before interest, tax, depreciation and amortisation) was ₹16,424 crore. Sun Pharma reports 40 manufacturing plants and more than 47,000 employees in the group.
- Who owns Sun Pharma?
- On 30 Sep 2026 Sun Pharma's promoter group, the Shanghvi family and its companies, held 52.68% of the shares. Foreign investors held 14.36%, Indian institutions 22.27% and other shareholders 10.70%. The promoter share fell from 54.48% in Jun 2026 because the Valia family was reclassified as public shareholders; no shares were sold.
- What is Sun Pharma's share of the Indian medicine market?
- Sun Pharma had an 8.5% share of India's medicine market in the 12 months to Jun 2026, with ₹21,538 crore of sales, according to AIOCD data quoted in Sun Pharma's Sep 2026 investor presentation.
- How much debt does Sun Pharma have?
- On 30 Sep 2026 Sun Pharma had borrowings of ₹2,694 crore and cash and liquid investments of ₹33,570 crore. Sun Pharma then allotted ₹7,816 crore of non-convertible debentures (bonds) on 26 Oct 2026.
- How did Sun Pharma do in Q2 FY27?
- In Q2 FY27 (Jul–Sep 2026) Sun Pharma's revenue rose 11.9% to ₹16,199 crore. Sun Pharma's profit for shareholders fell 36.2% to ₹1,989 crore, after ₹1,269 crore of one-off charges.
- Has Sun Pharma completed its purchase of Organon?
- No. Sun Pharma agreed on 27 Apr 2026 to buy Organon & Co. for US$14 a share in cash, and the deal had not closed as of Sun Pharma's 30 Oct 2026 earnings call.
- What dividend does Sun Pharma pay?
- Sun Pharma's dividend for FY26 was ₹16 per share (₹11 interim and ₹5 final), equal to 33.5% of its FY26 earnings per share of ₹47.8.
Sources (12)
- Annual Report FY26: Consolidated Financial Statements section
- Annual Report FY26: Chairman/MD message and Management Discussion & Analysis section
- Unaudited consolidated financial results Q2 FY27 (quarter and half year ended 30 Sep 2026)
- Press release: Sun Pharma reports Q4FY26 and FY26 results
- Investor presentation, September 2026 ("Creating Lasting Value")
- Shareholding pattern as of 30 Sep 2026 (NSE XBRL)
- Shareholding pattern as of 30 Jun 2026 (NSE XBRL)
- Intimation: shareholders approve reclassification from promoter group to public
- Intimation: allotment of non-convertible debentures of ₹7,816 crore
- Intimation and press release: definitive agreement to acquire Organon & Co.
- Q2 FY27 earnings call transcript (call 30 Oct 2026)
- Annual Report FY26: Board's Report and Corporate Governance section
Terms on this page
- Capital expenditure (capex)
- Credit rating
- Dividend payout ratio
- EBITDA
- FII and DII holding
- Free cash flow
- Market capitalisation
- Net debt
- Net profit
- Operating margin
Each explains the term in plain English, with the same number from other companies on Cityfort.
Go deeper
More detail from the same filings. Open any section.
12What it sells
12What it sells
What does Sun Pharma sell?
Branded medicines in India
Medicines sold under Sun Pharma's own brands and prescribed by doctors: ₹19,290 crore of sales in FY26. In AIOCD market data for the 12 months to Jun 2026, nervous-system and mental-health medicines were 19% of its India sales and heart medicines 17%.
Generic medicines in the US
Lower-priced versions of off-patent drugs. Sun Pharma says it is the 13th largest generics company in the US (IQVIA, 12 months to Jun 2026). It had 561 approved and 120 pending US generic drug applications on 30 Sep 2026.
Innovative (patented) medicines
Its own patented drugs, such as Ilumya (psoriasis), Cequa (dry eye), Winlevi (acne), Leqselvi (hair loss from alopecia areata) and Unloxcyt (a skin cancer). Sales were US$1,420 million in FY26, 20.7% of total sales excluding a milestone payment.
Medicines in emerging markets and other countries
Generic and branded medicines sold outside India and the US: ₹11,187 crore of formulation sales in emerging markets and ₹8,568 crore in the rest of the world in FY26.
Drug ingredients (API)
Active pharmaceutical ingredients, the substance in a medicine that does the work, sold to other companies: ₹2,185 crore in FY26.
What it does
- Does: Makes medicines in 40 plants around the world
- Does: Develops and launches its own patented drugs
- Does: Sells in more than 100 countries, including India and the US
- Does: Sells drug ingredients (API) to other companies
What it does not do
- Does not: Does not own Organon yet: the purchase agreed on 27 Apr 2026 had not closed as of the 30 Oct 2026 earnings call
- Does not: Does not report profit by region or by product, only sales
- Does not: Does not report innovative medicines as a separate segment: their sales sit inside the US, emerging-market and rest-of-world figures
13How the money flows
13How the money flows · FY26
How does money flow through Sun Pharma?
Money in
- Revenue from operations₹58,462 cr
- Other income (mostly on cash and investments)₹1,972 cr
The company
Sun Pharma
₹60,434 cr came in
Money out
- Materials and goods bought₹11,544 cr
- Employee costs₹11,419 cr
- Other running costs (research, marketing, freight), after a currency gain₹17,768 cr
- Depreciation, interest, part-owned companies' losses and minority share₹3,362 cr
- One-off charges (US legal settlements, labour codes, a dropped drug project)₹1,308 cr
- Income tax₹3,554 cr
- Net profit for Sun Pharma shareholders₹11,479 cr
- In FY26 Sun Pharma's medicines brought in ₹58,462 crore of revenue, plus ₹1,972 crore of other income.
- Materials took ₹11,544 crore and employees ₹11,419 crore.
- Other running costs, such as research and marketing, took ₹17,768 crore, after a ₹1,240 crore currency gain.
- One-off charges took ₹1,308 crore and income tax ₹3,554 crore.
- What was left for Sun Pharma's shareholders was ₹11,479 crore of profit.
14What it needs to run
14What it needs to run
What does Sun Pharma need to run?
Plants
40 manufacturing plants in the group. The Indian parent company alone reports 17 plants in India, including research centres (FY26 sustainability report, BRSR).
US approvals
On 30 Sep 2026: 561 approved and 120 pending US generic drug applications (ANDAs), and 58 approved and 12 pending new-drug applications (NDAs).
Research
₹3,554 crore spent on research and development in FY26, 6.1% of sales.
Sales team
Over 16,000 field staff in India on 30 Jun 2026, who visit doctors to explain Sun Pharma's medicines.
People
More than 47,000 employees in the group; 21,514 permanent employees in the Indian parent company on 31 Mar 2026.
Sources (6)
- Investor presentation, September 2026 ("Creating Lasting Value")
- Annual Report FY26: Chairman/MD message and Management Discussion & Analysis section
- Business Responsibility and Sustainability Report FY26 (standalone)
- Press release: Sun Pharma reports Q2FY27 results
- Press release: Sun Pharma reports Q4FY26 and FY26 results
- Annual Report FY26: Board's Report and Corporate Governance section
15Competitors and what protects it
15Competitors and what protects it
Who does Sun Pharma compete with?
Cipla
Sells medicines in India: ₹14,839 crore of India sales and a 5.8% share in the 12 months to Jun 2026, per AIOCD data in Sun Pharma's presentation.
Mankind Pharma
Sells medicines in India: ₹13,922 crore of India sales and a 5.5% share in the 12 months to Jun 2026, per AIOCD data in Sun Pharma's presentation.
Torrent Pharmaceuticals
Sells medicines in India: ₹12,801 crore of India sales and a 5.0% share in the 12 months to Jun 2026, per AIOCD data in Sun Pharma's presentation.
Lupin
Sells medicines in India: ₹8,972 crore of India sales and a 3.5% share in the 12 months to Jun 2026, per AIOCD data in Sun Pharma's presentation.
Dr. Reddy's Laboratories
Sells medicines in India: ₹7,956 crore of India sales and a 3.1% share in the 12 months to Jun 2026, per AIOCD data in Sun Pharma's presentation.
What protects the business
Each strength is scored 1 (weak) to 5 (strong) for the business, with the reason. It is not a rating of the share.
- Size in India4 of 5
₹21,538 crore of India medicine sales and an 8.5% share in the 12 months to Jun 2026 (AIOCD), against 5.9% for the next name in the same list (Abbott, Abbott Healthcare and Novo combined).
- Reach to doctors4 of 5
Over 16,000 field staff on 30 Jun 2026. Sun Pharma says it ranks first by prescriptions among 12 groups of doctors (SMSRC data).
- Brands3 of 5
30 of India's top 300 medicine brands (AIOCD, Jun 2026). Its top 10 brands were about 17% of India revenue, so sales are spread across many brands.
- Product approvals3 of 5
561 approved US generic applications and 58 approved new-drug applications on 30 Sep 2026, with 120 and 12 more pending.
- Cash on hand5 of 5
On 30 Sep 2026 cash and liquid investments of ₹33,570 crore exceeded borrowings of ₹2,694 crore. CRISIL rated Sun Pharma AAA/Stable on 13 Oct 2026.
Weak spot
US plant inspections
The FY26 annual report lists US FDA findings at four Indian plants: Halol has been on an FDA import alert since Dec 2022, and Mohali, Dadra and Baska carry warning letters or 'official action indicated' results.
Sources (6)
- Investor presentation, September 2026 ("Creating Lasting Value")
- Press release: Sun Pharma reports Q2FY27 results
- Unaudited consolidated financial results Q2 FY27 (quarter and half year ended 30 Sep 2026)
- Credit rating intimation with CRISIL rationale (13 Oct 2026, NCDs assigned AAA/Stable) and ICRA rationale
- Annual Report FY26: Consolidated Financial Statements section
- Intimation: US FDA classifies Baska facility inspection as OAI
16Where growth could come from
16Where growth could come from
Where could Sun Pharma's growth come from?
Management said on the Q4 FY26 call (22 May 2026) that it expects "high single-digit consolidated top line growth" in FY27, with research at 6–7% of sales, and gave no margin guidance. On the Q2 FY27 call (30 Oct 2026) it said it would keep that guidance.
Branded medicines in India
WorkingIndia sales +17.3%, Q2 FY27
India formulation sales rose from ₹4,735 crore in Q2 FY26 to ₹5,552 crore in Q2 FY27, 34.5% of the quarter's sales. Sun Pharma launched 14 products in India in the quarter, per its results release.
Status: Working, on track against what the company said.
Innovative medicines
WorkingUS$1,420 million, FY26 (+16.4% excluding a milestone payment)
Sales rose 6.9% to US$356 million in Q2 FY27. Management said on 30 Oct 2026 that Ilumya's US growth slowed, "driven by a mix of factors", and that Ilumya for psoriatic arthritis would have a soft US launch in November, with a full launch in the following months.
Status: Working, on track against what the company said.
US generics
MixedUS$455 million, Q2 FY27 (−8.2%)
US formulation sales, generics and innovative medicines together, fell from US$496 million in Q2 FY26. Management said the fall was largely due to lower sales of one generic, lenalidomide.
Status: Mixed, partly on track.
Organon purchase
EarlyEnterprise value US$11.75 billion; not closed
Sun Pharma agreed on 27 Apr 2026 to buy Organon & Co., which sells women's health medicines, biosimilars and other drugs in 140 countries, for US$14 a share in cash. Management said on 30 Oct 2026 that approvals were secured in most regions and it expects completion in Q4 FY27.
Status: Early, too early to judge.
New plant in Madhya Pradesh
New₹3,000 crore, approved 2 Dec 2025
A new medicine-making (formulations) plant to be built by subsidiary Sun Pharma Laboratories. No completion date has been filed.
Status: New, recently announced.
Status compares progress with what the company itself said it would do: Working = on track against what the company said; Mixed = partly on track; Behind = behind the company's own plan; New = recently announced; Early = too early to judge.
Sources (7)
- Q4 FY26 earnings call transcript (call 22 May 2026)
- Q2 FY27 earnings call transcript (call 30 Oct 2026)
- Press release: Sun Pharma reports Q2FY27 results
- Press release: Sun Pharma reports Q4FY26 and FY26 results
- Q2 FY27 earnings presentation
- Intimation and press release: definitive agreement to acquire Organon & Co.
- Intimation: approval of ₹3,000 crore greenfield formulations facility in Madhya Pradesh
17Financial strength and debt
17Financial strength · 30 Sep 2026
How much debt does Sun Pharma have?
- Total debt₹2,694 cr
- Cash and investments₹33,570 cr
- Net cash (cash minus debt)₹30,877 cr
- Net worth (shareholders' money)₹89,280 cr
- Debt to equity
- 0.03×
- ₹ of debt for every ₹1 of shareholders' money
- Borrowings exclude lease liabilities (rent owed under leases) of ₹548 crore.
- Cash and liquid investments = cash, other bank balances and current investments. Net worth is the equity belonging to Sun Pharma's shareholders.
- On 26 Oct 2026 Sun Pharma allotted ₹7,816 crore of non-convertible debentures (bonds). They are not in the 30 Sep 2026 figures.
- CRISIL said on 13 Oct 2026 that the Organon purchase would be funded with US$2.0–2.5 billion of cash and US$9.5–10.0 billion of debt, including about US$8.5 billion of Organon's own debt taken over.
- Sun Pharma's own measure of net cash, on its own definition, was US$3.3 billion on 30 Sep 2026.
- Moody's rated Sun Pharma Baa1 (Stable) and S&P BBB+ (Stable) on 8 Sep 2026, its first international ratings.
- On 31 Mar 2026 the group was disputing ₹711 crore of income-tax claims, and tax authorities had appealed ₹6,440 crore of orders that went in its favour.
Sources (6)
- Unaudited consolidated financial results Q2 FY27 (quarter and half year ended 30 Sep 2026)
- Annual Report FY26: Consolidated Financial Statements section
- Intimation: allotment of non-convertible debentures of ₹7,816 crore
- Credit rating intimation with CRISIL rationale (13 Oct 2026, NCDs assigned AAA/Stable) and ICRA rationale
- Q2 FY27 earnings presentation
- Intimation: international credit ratings (Moody's Baa1, S&P BBB+)
18Who owns it
18Who owns it · Q2 FY27
Who owns Sun Pharma?
- Promoters (founders or parent company)52.7%
- Foreign institutions (FII)14.4%
- Indian institutions (DII)22.3%
- Public and others10.7%
Promoter shares pledged
0.0% of promoter shares
A pledge means promoters gave shares as security for a loan. If the loan isn't repaid, the lender can sell them.
How ownership changed
* Pledged = share of the promoters' own holding reported as pledged. In older filings this can include shares “otherwise encumbered”; the governance flags say when.
Sources (14)
- Shareholding pattern as of 31 Dec 2023 (NSE XBRL)
- Shareholding pattern as of 31 Mar 2024 (NSE XBRL)
- Shareholding pattern as of 30 Jun 2024 (NSE XBRL)
- Shareholding pattern as of 30 Sep 2024 (NSE XBRL)
- Shareholding pattern as of 31 Dec 2024 (NSE XBRL)
- Shareholding pattern as of 31 Mar 2025 (NSE XBRL)
- Shareholding pattern as of 30 Jun 2025 (NSE XBRL)
- Shareholding pattern as of 30 Sep 2025 (NSE XBRL)
- Shareholding pattern as of 31 Dec 2025 (NSE XBRL)
- Shareholding pattern as of 31 Mar 2026 (NSE XBRL, revised filing)
- Shareholding pattern as of 30 Jun 2026 (NSE XBRL)
- Shareholding pattern as of 30 Sep 2026 (NSE XBRL)
- Intimation: receipt of requests for reclassification from promoter group to public (Valia family)
- Intimation: shareholders approve reclassification from promoter group to public
19What it does with profit
19What it does with profit
What does Sun Pharma do with its profit?
Dividend per share
₹16.00FY26
Dividend paid for each share, by financial year.
₹ per share
See the numbers
Money raised · 26 Oct 2026
Allotted non-convertible debentures (bonds) in two series, its first, after the board approved up to ₹10,000 crore on 12 Oct 2026. CRISIL and ICRA rated them AAA (Stable).
₹7,816 cr
Sources (8)
- Annual Report FY26: Board's Report and Corporate Governance section
- Annual Report FY23: Consolidated Financial Statements section
- Annual Report FY24: Consolidated Financial Statements section
- Annual Report FY25: Consolidated Financial Statements section
- Annual Report FY26: Consolidated Financial Statements section
- Intimation: allotment of non-convertible debentures of ₹7,816 crore
- Board outcome 12 Oct 2026: NCD issue up to ₹10,000 crore approved; independent director Gautam Doshi resigns
- Credit rating intimation with CRISIL rationale (13 Oct 2026, NCDs assigned AAA/Stable) and ICRA rationale
20Governance signals
20Governance signals
What do Sun Pharma's governance filings show?
- Auditor
- S R B C & Co LLP
- Auditor changes
- 30 Oct 2026: S R B C & Co LLP → Deloitte Haskins & Sells Chartered Accountants LLP (Mandatory rotation: S R B C's second five-year term ends at the AGM for FY27. The board proposed Deloitte from that AGM to the AGM for FY32, subject to shareholder approval.)
- Audit qualifications
- None reported
- Related-party dealings
- Related-party transaction amounts were not extracted for this page. The largest promoter-group shareholder, Shanghvi Finance Pvt Ltd, held 40.30% of Sun Pharma's shares on 30 Sep 2026.
- Credit rating
- CRISIL AAA (long term), A1+ (short term) (outlook Stable), 13 Oct 2026
A credit rating describes the company's ability to repay debt. It is not a rating of the share.
Flags to know about
pledge · 30 Sep 2026
Small promoter pledge
On 30 Sep 2026, 85,000 promoter-group shares were pledged as loan collateral, 0.01% of the promoter holding, down from 1.65% in Jun 2026 after the Valia family left the promoter group.
other · 26 Sep 2026
Valia family reclassified as public shareholders
Shareholders approved on 26 Sep 2026 moving Sudhir, Raksha and Krishna Valia (1.80% of shares) from the promoter group to the public category. No shares were sold; the promoter holding fell from 54.48% to 52.68%.
regulatory · 18 Dec 2025
US FDA findings at four plants
Halol: FDA import alert (Dec 2022), a warning letter (amended Oct 2023), and a Jun 2025 re-inspection classed 'official action indicated' (OAI). Mohali: consent-decree non-compliance letter (Apr 2023). Dadra: warning letter (Jun 2024). Baska: OAI (Dec 2025); Sun Pharma still supplies the US from Baska.
disclosure · 2 Nov 2026
Assam eye-care recall disclosed on the call
Sun Pharma said on its 30 Oct 2026 call that in Aug 2026 it voluntarily recalled 11 eye-care products from its Assam plant, paused production there and informed India's drug regulator. On 2 Nov 2026 it told the exchanges this happened in Aug 2026 and that it did not consider it material for separate disclosure.
other · 11 Sep 2026
US antitrust settlements
Sun Pharma has settled US lawsuits alleging breaches of competition (antitrust) law, without admitting wrongdoing, per its filings: US$485 million in Mar 2022, a US$200 million end-payer settlement in FY26, and ₹923 crore including legal costs with one plaintiff in the generic-drug pricing case in Q2 FY27.
other · 12 Oct 2026
Independent director resigned
Gautam Doshi resigned as an independent director on 12 Oct 2026, citing personal reasons. He confirmed there were no material reasons other than those stated.
Sources (15)
- Annual Report FY26: Board's Report and Corporate Governance section
- Board outcome: appointment of Deloitte Haskins & Sells as statutory auditors (mandatory rotation)
- Shareholding pattern as of 30 Sep 2026 (NSE XBRL)
- Credit rating intimation with CRISIL rationale (13 Oct 2026, NCDs assigned AAA/Stable) and ICRA rationale
- Shareholding pattern as of 30 Jun 2026 (NSE XBRL)
- Intimation: receipt of requests for reclassification from promoter group to public (Valia family)
- Intimation: shareholders approve reclassification from promoter group to public
- Annual Report FY26: Consolidated Financial Statements section
- Intimation: US FDA classifies Baska facility inspection as OAI
- Q2 FY27 earnings call transcript (call 30 Oct 2026)
- Clarification on news report about the Assam facility
- Annual Report FY23: Consolidated Financial Statements section
- Unaudited consolidated financial results Q2 FY27 (quarter and half year ended 30 Sep 2026)
- Intimation: settlement agreement with a plaintiff in the generic drug pricing antitrust litigation (US)
- Board outcome 12 Oct 2026: NCD issue up to ₹10,000 crore approved; independent director Gautam Doshi resigns
21What the market paid
21What the market paid · price as of 11 Nov 2026
What did the market pay for Sun Pharma on 11 Nov 2026?
Price as of 11 Nov 2026 (shown for education; prices change daily).
Price as of 11 Nov 2026: ₹1,902.30, the NSE closing price. Market value = price × 2,399,334,970 shares = ₹456,425 crore. P/E = market value ÷ profit of the last four quarters (Q3 FY26 to Q2 FY27, ₹10,966 crore) = 41.6. P/B = market value ÷ shareholders' equity on 30 Sep 2026 (₹89,280 crore) = 5.1. Dividend yield = FY26 dividend of ₹16 ÷ price = 0.84%.
- Share price
- ₹1,902.30
- Market value (market cap)
- ₹456,425 cr
- P/E
- 41.6×
- P/B
- 5.1×
Source: NSE capital market bhavcopy, 11 Nov 2026 (SUNPHARMA EQ close); Shareholding pattern as of 30 Sep 2026 (NSE XBRL); Unaudited consolidated financial results Q2 FY27 (quarter and half year ended 30 Sep 2026) and 4 more
Sources (7)
- NSE capital market bhavcopy, 11 Nov 2026 (SUNPHARMA EQ close)
- Shareholding pattern as of 30 Sep 2026 (NSE XBRL)
- Unaudited consolidated financial results Q2 FY27 (quarter and half year ended 30 Sep 2026)
- Unaudited consolidated financial results Q1 FY27 (quarter ended 30 Jun 2026)
- Audited consolidated financial results Q4 FY26 and FY26
- Unaudited consolidated financial results Q3 FY26 (quarter ended 31 Dec 2025)
- Annual Report FY26: Board's Report and Corporate Governance section
22How it got here
22How it got here
How did Sun Pharma get here?
1983
Milestone
Started with five products
Sun Pharma began in 1983 with five products, according to its investor presentation.
1994
Milestone
Listed on the stock market
Its 1994 public issue raised ₹55 crore (₹550 million).
1997
Business-model change
Entered US generics
Bought Caraco, its entry into the US generics market.
2014
Business-model change
Licensed Ilumya from Merck
Took the psoriasis drug tildrakizumab (Ilumya), the start of its patented-medicine business.
2015
Business-model change
Merged Ranbaxy
The Ranbaxy merger made Sun Pharma larger in India and in US generics.
2022
Crisis
Antitrust settlement and Halol import alert
A US$485 million US antitrust settlement in Mar 2022 cut FY22 profit; in Dec 2022 the US FDA put the Halol plant on import alert.
2024
Milestone
Took full ownership of Taro
Bought out Taro's minority shareholders for ₹2,900 crore. Sun Pharma first acquired Taro, an Israeli maker of skin-care generics, in 2010.
2025
Milestone
Checkpoint deal and new managing director
Bought Checkpoint Therapeutics (skin-cancer drug Unloxcyt) on 30 May 2025; Kirti Ganorkar became Managing Director on 1 Sep 2025.
2026
Business-model change
Agreed to buy Organon
Signed an agreement on 27 Apr 2026 to buy Organon & Co. for an enterprise value of US$11.75 billion. The deal had not closed as of the 30 Oct 2026 earnings call.
Sources (7)
- Investor presentation, September 2026 ("Creating Lasting Value")
- Annual Report FY26: Chairman/MD message and Management Discussion & Analysis section
- Annual Report FY23: Consolidated Financial Statements section
- Annual Report FY26: Consolidated Financial Statements section
- Annual Report FY26: Board's Report and Corporate Governance section
- Intimation and press release: definitive agreement to acquire Organon & Co.
- Q2 FY27 earnings call transcript (call 30 Oct 2026)
23Sources and changes
Where every number on this page comes from
Sources (45 documents)
- S1Annual Report FY26: Consolidated Financial Statements section · Sun Pharmaceutical Industries Ltd (company IR site; same document filed with NSE/BSE) · Tier 1: company or exchange filing · 6 Jul 2026
- S2Annual Report FY26: Chairman/MD message and Management Discussion & Analysis section · Sun Pharmaceutical Industries Ltd (company IR site; same document filed with NSE/BSE) · Tier 1: company or exchange filing · 6 Jul 2026
- S3Annual Report FY26: Board's Report and Corporate Governance section · Sun Pharmaceutical Industries Ltd (company IR site; same document filed with NSE/BSE) · Tier 1: company or exchange filing · 6 Jul 2026
- S4Business Responsibility and Sustainability Report FY26 (standalone) · Sun Pharmaceutical Industries Ltd (company IR site; same document filed with NSE/BSE) · Tier 1: company or exchange filing · 6 Jul 2026
- S5Annual Report FY25: Consolidated Financial Statements section · Sun Pharmaceutical Industries Ltd (company IR site; same document filed with NSE/BSE) · Tier 1: company or exchange filing · 4 Jul 2025
- S6Annual Report FY24: Consolidated Financial Statements section · Sun Pharmaceutical Industries Ltd (company IR site; same document filed with NSE/BSE) · Tier 1: company or exchange filing · 8 Jul 2024
- S7Annual Report FY23: Consolidated Financial Statements section · Sun Pharmaceutical Industries Ltd (company IR site; same document filed with NSE/BSE) · Tier 1: company or exchange filing · 27 Jul 2023
- S9Unaudited consolidated financial results Q2 FY27 (quarter and half year ended 30 Sep 2026) · Sun Pharmaceutical Industries Ltd (company IR site; same document filed with NSE/BSE) · Tier 1: company or exchange filing · 30 Oct 2026
- S10Press release: Sun Pharma reports Q2FY27 results · Sun Pharmaceutical Industries Ltd (company IR site; same document filed with NSE/BSE) · Tier 1: company or exchange filing · 30 Oct 2026
- S11Q2 FY27 earnings presentation · Sun Pharmaceutical Industries Ltd (company IR site; same document filed with NSE/BSE) · Tier 1: company or exchange filing · 30 Oct 2026
- S12Q2 FY27 earnings call transcript (call 30 Oct 2026) · Sun Pharmaceutical Industries Ltd (company IR site; same document filed with NSE/BSE) · Tier 1: company or exchange filing · 4 Nov 2026
- S13Unaudited consolidated financial results Q1 FY27 (quarter ended 30 Jun 2026) · Sun Pharmaceutical Industries Ltd (company IR site; same document filed with NSE/BSE) · Tier 1: company or exchange filing · 31 Jul 2026
- S17Audited consolidated financial results Q4 FY26 and FY26 · Sun Pharmaceutical Industries Ltd (company IR site; same document filed with NSE/BSE) · Tier 1: company or exchange filing · 22 May 2026
- S18Press release: Sun Pharma reports Q4FY26 and FY26 results · Sun Pharmaceutical Industries Ltd (company IR site; same document filed with NSE/BSE) · Tier 1: company or exchange filing · 22 May 2026
- S19Q4 FY26 earnings call transcript (call 22 May 2026) · Sun Pharmaceutical Industries Ltd (company IR site; same document filed with NSE/BSE) · Tier 1: company or exchange filing · 29 May 2026
- S20Unaudited consolidated financial results Q3 FY26 (quarter ended 31 Dec 2025) · Sun Pharmaceutical Industries Ltd (company IR site; same document filed with NSE/BSE) · Tier 1: company or exchange filing · 31 Jan 2026
- S25Press release: Sun Pharma reports Q4FY23 and FY23 results · Sun Pharmaceutical Industries Ltd (company IR site; same document filed with NSE/BSE) · Tier 1: company or exchange filing · 26 May 2023
- S26Q4 FY25 earnings call transcript (call 22 May 2025) · Sun Pharmaceutical Industries Ltd (company IR site; same document filed with NSE/BSE) · Tier 1: company or exchange filing · 29 May 2025
- S27Investor presentation, September 2026 ("Creating Lasting Value") · Sun Pharmaceutical Industries Ltd (company IR site; same document filed with NSE/BSE) · Tier 1: company or exchange filing · 22 Sep 2026
- S28Shareholding pattern as of 31 Dec 2023 (NSE XBRL) · NSE (company filing) · Tier 1: company or exchange filing · 16 Jan 2024
- S29Shareholding pattern as of 31 Mar 2024 (NSE XBRL) · NSE (company filing) · Tier 1: company or exchange filing · 18 Apr 2024
- S30Shareholding pattern as of 30 Jun 2024 (NSE XBRL) · NSE (company filing) · Tier 1: company or exchange filing · 19 Jul 2024
- S31Shareholding pattern as of 30 Sep 2024 (NSE XBRL) · NSE (company filing) · Tier 1: company or exchange filing · 16 Oct 2024
- S32Shareholding pattern as of 31 Dec 2024 (NSE XBRL) · NSE (company filing) · Tier 1: company or exchange filing · 20 Jan 2025
- S33Shareholding pattern as of 31 Mar 2025 (NSE XBRL) · NSE (company filing) · Tier 1: company or exchange filing · 17 Apr 2025
- S34Shareholding pattern as of 30 Jun 2025 (NSE XBRL) · NSE (company filing) · Tier 1: company or exchange filing · 21 Jul 2025
- S35Shareholding pattern as of 30 Sep 2025 (NSE XBRL) · NSE (company filing) · Tier 1: company or exchange filing · 16 Oct 2025
- S36Shareholding pattern as of 31 Dec 2025 (NSE XBRL) · NSE (company filing) · Tier 1: company or exchange filing · 15 Jan 2026
- S37Shareholding pattern as of 31 Mar 2026 (NSE XBRL, revised filing) · NSE (company filing) · Tier 1: company or exchange filing · 17 Jun 2026
- S38Shareholding pattern as of 30 Jun 2026 (NSE XBRL) · NSE (company filing) · Tier 1: company or exchange filing · 17 Jul 2026
- S39Shareholding pattern as of 30 Sep 2026 (NSE XBRL) · NSE (company filing) · Tier 1: company or exchange filing · 15 Oct 2026
- S40Credit rating intimation with CRISIL rationale (13 Oct 2026, NCDs assigned AAA/Stable) and ICRA rationale · Sun Pharmaceutical Industries Ltd (filing to NSE/BSE) · Tier 2: rating agency or regulator · 13 Oct 2026
- S44Intimation: international credit ratings (Moody's Baa1, S&P BBB+) · Sun Pharmaceutical Industries Ltd (filing to NSE/BSE) · Tier 1: company or exchange filing · 8 Sep 2026
- S45Intimation and press release: definitive agreement to acquire Organon & Co. · Sun Pharmaceutical Industries Ltd (filing to NSE/BSE) · Tier 1: company or exchange filing · 27 Apr 2026
- S46Intimation: receipt of requests for reclassification from promoter group to public (Valia family) · Sun Pharmaceutical Industries Ltd (filing to NSE/BSE) · Tier 1: company or exchange filing · 14 May 2026
- S47Intimation: shareholders approve reclassification from promoter group to public · Sun Pharmaceutical Industries Ltd (filing to NSE/BSE) · Tier 1: company or exchange filing · 26 Sep 2026
- S48Board outcome: appointment of Deloitte Haskins & Sells as statutory auditors (mandatory rotation) · Sun Pharmaceutical Industries Ltd (filing to NSE/BSE) · Tier 1: company or exchange filing · 30 Oct 2026
- S50Intimation: approval of ₹3,000 crore greenfield formulations facility in Madhya Pradesh · Sun Pharmaceutical Industries Ltd (filing to NSE/BSE) · Tier 1: company or exchange filing · 2 Dec 2025
- S51Intimation: US FDA classifies Baska facility inspection as OAI · Sun Pharmaceutical Industries Ltd (filing to NSE/BSE) · Tier 1: company or exchange filing · 18 Dec 2025
- S52Clarification on news report about the Assam facility · Sun Pharmaceutical Industries Ltd (filing to NSE/BSE) · Tier 1: company or exchange filing · 2 Nov 2026
- S53Intimation: settlement agreement with a plaintiff in the generic drug pricing antitrust litigation (US) · Sun Pharmaceutical Industries Ltd (filing to NSE/BSE) · Tier 1: company or exchange filing · 11 Sep 2026
- S54Board outcome 12 Oct 2026: NCD issue up to ₹10,000 crore approved; independent director Gautam Doshi resigns · Sun Pharmaceutical Industries Ltd (filing to NSE/BSE) · Tier 1: company or exchange filing · 12 Oct 2026
- S55Intimation: update on Lipitor antitrust litigation (US appeals court affirms judgment for the company) · Sun Pharmaceutical Industries Ltd (filing to NSE/BSE) · Tier 1: company or exchange filing · 17 Aug 2026
- S56Intimation: allotment of non-convertible debentures of ₹7,816 crore · Sun Pharmaceutical Industries Ltd (filing to NSE/BSE) · Tier 1: company or exchange filing · 26 Oct 2026
- S57NSE capital market bhavcopy, 11 Nov 2026 (SUNPHARMA EQ close) · National Stock Exchange of India · Tier 1: company or exchange filing · 11 Nov 2026
Changes to this page (v1 · 11 Nov 2026)
- v1 · 11 Nov 2026First version. (first version)
Numbers come only from tier 1 and tier 2 sources. Read how we research.
Disclaimer
For learning only. Cityfort is not a SEBI-registered adviser and does not recommend buying or selling any security. Prices shown are dated and may be out of date.
Investing in securities involves risk, including loss of capital. Before making any investment decision, do your own research and consider consulting a SEBI-registered investment adviser.
Cityfort, its owners and contributors may or may not hold securities of companies covered. Content is not an offer or solicitation to buy or sell any security.
Read the full disclaimerHide the full disclaimer
Cityfort publishes educational content that explains how listed companies work. Cityfort is not registered with the Securities and Exchange Board of India (SEBI) as an Investment Adviser or Research Analyst and does not provide investment advice, recommendations, ratings, price targets or any opinion on whether to buy, sell or hold any security.
All information is taken from publicly available sources, mainly company filings on BSE and NSE, which are listed on each page with dates. We work to keep it accurate and correct errors publicly, but we do not guarantee that it is complete, accurate or up to date. Any market price or price-based ratio shown is dated, may be out of date by the time you read it, and is included only to explain concepts.
Statements by company management are reported as statements, with their date and source; they are not our forecasts.